EP 1411128 B1 20080924 - RECOMBINANT VIRAL VECTORS CONTAINING THE HUMAN UROKINASE PLASMINOGEN ACTIVATOR GENE AND THEIR UTILIZATION IN THE TREATMENT OF HEPATIC FIBROSIS
Title (en)
RECOMBINANT VIRAL VECTORS CONTAINING THE HUMAN UROKINASE PLASMINOGEN ACTIVATOR GENE AND THEIR UTILIZATION IN THE TREATMENT OF HEPATIC FIBROSIS
Title (de)
REKOMBINANTE VIRALE VEKTOREN MIT DEM GEN FÜR DEN MENSCHLICHEN UROKINASE-PLASMINAKTIVATOR UND DEREN VERWENDUNG BEI DER BEHANDLUNG VON LEBERFIBROSE
Title (fr)
VECTEURS RECOMBINES VIRAUX CONTENANT LE GENE HUMAIN DE L'ACTIVATEUR DU PLASMINOGENE DERIVE DE L'UROKINASE ET LEUR UTILISATION DANS LE TRAITEMENT DE LA FIBROSE HEPATIQUE
Publication
Application
Priority
- MX 0000050 W 20001130
- MX PA00011713 A 20001128
Abstract (en)
[origin: EP1411128A1] Preparing recombinant (non-)viral vectors (A) by cloning reporter gene (RG), and modified cDNA (I) of a therapeutic gene (II) that encodes a protein (III) useful for treating fibrosis (hepatic, pulmonary, renal, cardiac or pancreatic), keloids and hypertrophic scars in mammals, including humans, is new. An independent claim is also included for a recombinant adenoviral vector (A') produced by the new method. ACTIVITY : Hepatotropic; Antifibrotic; Vulnerary. MECHANISM OF ACTION : (II) induce degradation of collagen. Liver cirrhosis was induced in rats using tetrachloromethane, then the animals injected (iliac vein) with a single dose of 6X10 1> 1> viral particles/kg of vector pAd.PGk-delta Ndelta C-huPA (expressing human urokinase). Analysis of the liver after 8 days indicated levels (international units/l) of ALT, AST and alkaline phosphatase of 88.5, 137 and 205; compare 410, 2250 and 454 for animals injected with an irrelevant vector; and total bilirubin was 0.94 (compare 1.4) mg/dl. Hematological parameters were not affected and the treatment significantly increased expression of matrix metalloprotease-2; reduced expression of collagens types I, III and IV, and stimulated mitosis of hepatocytes.
IPC 8 full level
C12N 15/09 (2006.01); C12N 15/861 (2006.01); A61K 35/76 (2015.01); A61K 35/761 (2015.01); A61K 38/00 (2006.01); A61K 38/17 (2006.01); A61K 38/18 (2006.01); A61K 38/49 (2006.01); A61K 48/00 (2006.01); A61P 1/16 (2006.01); A61P 1/18 (2006.01); A61P 9/00 (2006.01); A61P 11/00 (2006.01); A61P 13/12 (2006.01); A61P 17/02 (2006.01); A61P 43/00 (2006.01); C12N 7/00 (2006.01); C12N 9/72 (2006.01); C12N 15/12 (2006.01); C12Q 1/68 (2006.01)
CPC (source: EP US)
A61K 38/179 (2013.01 - EP US); A61K 38/1833 (2013.01 - EP US); A61P 1/16 (2018.01 - EP); A61P 1/18 (2018.01 - EP); A61P 9/00 (2018.01 - EP); A61P 11/00 (2018.01 - EP); A61P 13/12 (2018.01 - EP); A61P 17/02 (2018.01 - EP); A61P 43/00 (2018.01 - EP); C12N 7/00 (2013.01 - EP US); C12N 9/6462 (2013.01 - EP US); C12N 15/86 (2013.01 - EP US); C12Y 304/21073 (2013.01 - EP US); A61K 38/00 (2013.01 - EP US); A61K 48/00 (2013.01 - EP US); C12N 2710/10343 (2013.01 - EP US)
Designated contracting state (EPC)
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR
DOCDB simple family (publication)
EP 1411128 A1 20040421; EP 1411128 B1 20080924; AR 031436 A1 20030924; AT E409234 T1 20081015; AU 1737401 A 20020611; CA 2430367 A1 20020606; CA 2430367 C 20121030; CY 1108667 T1 20140409; DE 00980071 T1 20050331; DE 60040352 D1 20081106; DK 1411128 T3 20090202; ES 2226597 T1 20050401; ES 2226597 T3 20090316; HK 1062454 A1 20041105; JP 2004527224 A 20040909; JP 4733337 B2 20110727; MX PA00011713 A 20020531; PT 1411128 E 20081230; TR 200403256 T3 20050221; US 2004097455 A1 20040520; US 7807457 B2 20101005; WO 0244393 A1 20020606
DOCDB simple family (application)
EP 00980071 A 20001130; AR P010105552 A 20011128; AT 00980071 T 20001130; AU 1737401 A 20001130; CA 2430367 A 20001130; CY 081101456 T 20081216; DE 00980071 T 20001130; DE 60040352 T 20001130; DK 00980071 T 20001130; ES 00980071 T 20001130; HK 04103987 A 20040603; JP 2002546741 A 20001130; MX 0000050 W 20001130; MX PA00011713 A 20001128; PT 00980071 T 20001130; TR 200403256 T 20001130; US 43298903 A 20031024